Michel Vounatsos, Biogen CEO (Credit: World Economic Forum/Valeriano Di Domenico)
November 10, 2021 10:37 AM EST
FDA+

Amid an al­ready slow roll­out, Bio­gen's Aduhelm could soon face price com­pe­ti­tion — re­port

Nicole DeFeudis

Editor

De­spite the snail-paced roll­out of Bio­gen’s con­tro­ver­sial­ly ap­proved Alzheimer’s treat­ment Aduhelm, CEO Michel Vounatsos in­sist­ed on the lat­est earn­ings call that he’s con­fi­dent in the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis turns to BioAge for new tar­gets based on longevi­ty and ex­er­cise

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Up­dat­ed: Flag­ship gene ther­a­py start­up Ring Ther­a­peu­tics near­ly halves work­force as CEO de­parts

Post-Hoc: Biose­cure is dead. Long live Biose­cure? 

US spent $450B on drugs last year, CMS says, with new obe­si­ty and di­a­betes drugs adding to to­tal

No­vo Nordisk part­ners with Broad In­sti­tute spin­out Pho­tys af­ter the star­tup's lay­offs

A service from the Financial Times